Brokerages Set BioNTech SE (NASDAQ:BNTX) PT at $120.40

Shares of BioNTech SE (NASDAQ:BNTX) have been assigned a consensus rating of “Hold” from the ten ratings firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $120.40.

Several analysts recently issued reports on the company. JPMorgan Chase & Co. lowered their price target on BioNTech from $99.00 to $90.00 and set an “underweight” rating for the company in a report on Friday, March 22nd. HC Wainwright reiterated a “buy” rating and issued a $107.00 price target on shares of BioNTech in a report on Wednesday, April 17th. UBS Group decreased their price objective on shares of BioNTech from $110.00 to $101.00 and set a “neutral” rating for the company in a research report on Wednesday, March 27th. BMO Capital Markets decreased their price objective on shares of BioNTech from $127.00 to $123.00 and set an “outperform” rating for the company in a research report on Thursday, March 21st. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $171.00 price objective on shares of BioNTech in a research report on Thursday, March 21st.

Hedge Funds Weigh In On BioNTech

Large investors have recently modified their holdings of the stock. CWM LLC lifted its position in shares of BioNTech by 657.6% during the fourth quarter. CWM LLC now owns 250 shares of the company’s stock worth $26,000 after purchasing an additional 217 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of BioNTech by 121.0% during the first quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after purchasing an additional 150 shares during the last quarter. Frazier Financial Advisors LLC bought a new position in shares of BioNTech during the fourth quarter worth about $30,000. Covestor Ltd bought a new position in BioNTech in the third quarter worth about $32,000. Finally, First Horizon Advisors Inc. bought a new position in BioNTech in the fourth quarter worth about $38,000. Institutional investors own 15.52% of the company’s stock.

BioNTech Stock Up 1.4 %

Shares of NASDAQ BNTX opened at $88.01 on Tuesday. BioNTech has a 12-month low of $85.21 and a 12-month high of $125.83. The company has a market cap of $20.92 billion, a P/E ratio of 21.36 and a beta of 0.23. The company has a current ratio of 9.43, a quick ratio of 9.26 and a debt-to-equity ratio of 0.01. The stock has a fifty day moving average price of $91.09 and a 200 day moving average price of $96.98.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Wednesday, March 20th. The company reported $2.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.64 by ($0.59). BioNTech had a net margin of 24.26% and a return on equity of 4.60%. The company had revenue of $1.59 billion during the quarter, compared to analyst estimates of $2.04 billion. Research analysts anticipate that BioNTech will post -1.73 EPS for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.